Wang Lan, Miao Yiyan, Gu Yihang, Kawaguchi Tomoya, Mizutani Megumi, Nakai Toshiyuki, Watanabe Tetsuya, Asai Kazuhisa, Zhang Hui, Cai Wenwen, Tani Yoko, Kaneda Hiroyasu
Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, China.
The Jiangyin Clinical College of Xuzhou Medical University, China.
Intern Med. 2025 Sep 1;64(17):2524-2533. doi: 10.2169/internalmedicine.4808-24. Epub 2025 Mar 1.
With its increasing incidence, lung cancer has become one of the leading causes of cancer-related deaths worldwide, posing a great threat to the health and lives of patients. Due to varying economic and cultural backgrounds, there are significant differences in clinical treatment practices and related basic research on lung cancer between Japan and China. These differences are mainly reflected in many aspects, such as cancer prevention, cancer treatment, provision of medical insurance, patient compliance, medical education system, and sources of research funding. By understanding these differences, Japan and China can learn from each other, make progress together, and strengthen further exchanges and cooperation, which will help improve the long-term efficacy of lung cancer treatment and improve patients' clinical outcomes.
随着肺癌发病率的不断上升，它已成为全球癌症相关死亡的主要原因之一，对患者的健康和生命构成了巨大威胁。由于经济和文化背景不同，日本和中国在肺癌的临床治疗实践及相关基础研究方面存在显著差异。这些差异主要体现在多个方面，如癌症预防、癌症治疗、医疗保险提供、患者依从性、医学教育体系以及研究资金来源等。通过了解这些差异，日本和中国可以相互学习、共同进步，并加强进一步的交流与合作，这将有助于提高肺癌治疗的长期疗效并改善患者的临床结局。
